Advertisement
News
Subscribe to MDT Magazine News

Metzger takes Mersana Therapeutics COO post

April 20, 2011 7:37 am | by Mass High Tech: The Journal of New England Technology | Comments

Mersana Therapeutics Inc. has named Michael Metzger, formerly of Forest Laboratories Inc., as executive vice president and chief operating officer of the Cambridge cancer therapeutics company.

Siemens Applauds First Health System Customers to Successfully Attest to Meaningful Use

April 20, 2011 6:37 am | by Bio-Medicine.Org | Comments

MALVERN, Pa., April 20, 2011 /- Today, Siemens Healthcare (NYSE: SI ) applauds its first two health system customers to successfully attest and achieve Stage 1 Meaningful Use of an Electronic Health Record, as defined in the Centers for Medicare & Medicaid Services (CMS) EHR Incentive...

TOPICS:

Merrimack Pharmaceuticals Announces that Recruitment is Open in a Phase 1 Combination Study of MM-111 with Multiple Treatment Regimens in HER2 Positive Patients

April 20, 2011 6:37 am | by Bio-Medicine.Org | Comments

CAMBRIDGE, Mass., April 20, 2011 /- Merrimack Pharmaceuticals, Inc. announced today that five patients have received therapy in a Phase I clinical study combining MM-111 with multiple standard treatment regimens for patients with advanced HER2 positive (HER2+) solid tumors. (Logo:...

TOPICS:
Advertisement

Neurelis Announces Completion of Dosing in Study of Intranasal Diazepam

April 20, 2011 6:35 am | by Bio-Medicine.Org | Comments

SAN DIEGO, April 20, 2011 /- Neurelis, Inc. today announced the completion of subject dosing in a randomized crossover study assessing diazepam pharmacokinetics and bioavailability after administration of two proprietary formulations of intranasal diazepam and intravenous injection....

TOPICS:

ABC News Reports on Aethlon Medical

April 20, 2011 6:34 am | by Bio-Medicine.Org | Comments

SAN DIEGO, April 20, 2011 /- Aethlon Medical, Inc. (OTCBB:AEMD), the pioneer in developing therapeutic filtration devices to address infectious disease and cancer, disclosed today that it is the subject of an ABC news story that can be accessed online at:...

TOPICS:

Commidea implements payment system for Nuffield Health Hospitals

April 20, 2011 6:32 am | by RealWire | Comments

Payment processing provider delivers 30 site rolloutLondon, 20 April 2011 - Payment processing provider Commidea has completed the implementation of its payment system, Ocius for PC across 30 Nuffield Health hospitals nationwide and in its UK contact centre. Ocius for PC has enabled...

TOPICS:

Repeated stress in pregnancy linked to children's behavior

April 20, 2011 5:38 am | by EurekAlert | Comments

(Research Australia) Research from Perth's Telethon Institute for Child Health Research has found a link between the number of stressful events experienced during pregnancy and increased risk of behavioral problems in children.The study has just been published online in the latest...

TOPICS:

ESHRE sets standards for cross-border reproductive care

April 20, 2011 5:38 am | by EurekAlert | Comments

(European Society of Human Reproduction and Embryology) The European Society of Human Reproduction and Embryology is setting the first ever standards in cross-border reproductive care. The safety of patients, gamete donors, surrogates and future children take center stage in...

TOPICS:
Advertisement

Intersolar Europe ? Connecting Solar Business

April 20, 2011 5:38 am | by I-Micronews | Comments

Intersolar Europe to showcase more efficient technologies and innovative systems and machines for photovoltaic production

Valeant Pharmaceuticals Announces Redemption of 4.0% Convertible Subordinated Notes Due 2013

April 20, 2011 5:35 am | by Bio-Medicine.Org | Comments

MISSISSAUGA, Ontario, April 20, 2011 /- Valeant Pharmaceuticals International, Inc. (NYSE: VRX ) today announced that it will redeem all of the outstanding 4.0% Convertible Subordinated Notes due 2013 (the "Notes") of its wholly-owned subsidiary, Valeant Pharmaceuticals International, on...

TOPICS:

Mylan Launches Generic Version of Famvir® Tablets

April 20, 2011 5:34 am | by Bio-Medicine.Org | Comments

PITTSBURGH, April 20, 2011 /- Mylan Inc. (Nasdaq: MYL ) today announced that its subsidiary Mylan Pharmaceuticals Inc. has launched Famciclovir Tablets, 125 mg, 250 mg and 500 mg, the generic version of Novartis' Famvir® Tablets, a treatment for herpes.   Famciclovir Tablets had...

TOPICS:

PositiveID Corporation Develops Sample Prep Application to Improve Detection and Processing of Biological Samples

April 20, 2011 5:33 am | by PositiveID | Comments

PositiveID Corporation Develops Sample Prep Application to Improve Detection and Processing of Biological Samples

TOPICS:

Patients Living with Sjogren's Syndrome Encourage Communities to "Defy the Dry"

April 20, 2011 5:32 am | by Bio-Medicine.Org | Comments

PARSIPPANY, N.J. and BETHESDA, Md., April 20, 2011 /- The Sjogren's Syndrome Foundation (SSF), in partnership with Daiichi Sankyo Inc., today announced the launch of the Defy the Dry™ campaign, an educational initiative to ignite patient-physician dialogue about dryness symptoms....

TOPICS:

Bluebird bio lines its nest with $30M financing

April 20, 2011 4:36 am | by Mass High Tech: The Journal of New England Technology | Comments

Cambridge gene-therapy company bluebird bio has added Arch Venture Partners to its roster of backers for its latest round that brought in $30 million in financing, which the company describes in a press release as all part of its master plan to move its gene therapy platform quickly forward.

Bluebird bio lines its nest with $30M

April 20, 2011 3:37 am | by Mass High Tech: The Journal of New England Technology | Comments

Cambridge gene-therapy company bluebird bio has added Arch Venture Partners to its roster of backers for its latest round that brought in $30 million in financing, which the company describes in a press release as all part of its master plan to move its gene therapy platform quickly forward.

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading